Mast Cells as Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis?

Chapter

Abstract

Results of mast cell staining in early and recent studies agree surprisingly well, even though different staining methods have been applied. Increased mast cell counts in subepithelial tissue and in the detrusor muscle are characteristic for bladder pain syndrome/interstitial cystitis (BPS/IC) with Hunner’s lesion, or “classic interstitial cystitis”, but not for BPS/IC without Hunner’s lesion or overactive bladder syndrome (OAB). BPS/IC without Hunner’s lesion and OAB cannot be differentiated by mast cell counts, activation or localization. Recent studies found that mast cell evaluation is not necessary for the diagnosis of BPS/IC, especially because cystoscopy is sufficient to identify BPS/IC with Hunner’s lesion. Other histological markers, such as a defective urothelium, the presence of lymphocytic infiltration/lymphocyte aggregates and submucosal sensory hyperinnervation are better criteria to distinguish BPS/IC without Hunner’s lesion from OAB. The origin of BPS/IC still remains unknown. Future goals should include the identification of early disease forms and adequate therapies to prevent disease progression. Objective, reliable and preferentially non-invasive markers for diagnosis and treatment monitoring have to be determined.

Keywords

Mast cells Diagnosis Histopathology Immunohistochemistry Toluidine blue staining 

References

  1. 1.
    Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. American Urological Association (AUA) guideline. 2014:1–45.Google Scholar
  2. 2.
    Belknap S, Blalock, E, Erickson D. The challenges of interstitial cystitis: current status and future prospects. Drugs 2015;75:2057–63.Google Scholar
  3. 3.
    Aldenborg F, Fall M, Enerback L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology. 1986;58:411–6.PubMedPubMedCentralGoogle Scholar
  4. 4.
    van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Nordling J, Anjum FH, Bade JJ, Bouchelouche K, Bouchelouche P, Cervigni M, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol. 2004;45:662–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Larsen S, Thompson SA, Hald T, Barnard RJ, Gilpin CJ, Dixon JS, et al. Mast cells in interstitial cystitis. Br J Urol. 1982;54:283–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Yamada T, Murayama T, Mita H, Akiyama K. Subtypes of bladder mast cells in interstitial cystitis. Int J Urol. 2000;7:292–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Gamper M, Regauer S, Welter J, Eberhard J, Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol. 2015;193:1994–2000.CrossRefPubMedGoogle Scholar
  9. 9.
    Regauer S, Gamper M, Fehr MK, Viereck V. Sensory hyperinnervation distinguishes bladder pain syndrome/interstitial cystitis from overactive bladder syndrome. J Urol. 2017;197:159–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Marianne Gamper
    • 1
  • Sigrid Regauer
    • 2
  • Volker Viereck
    • 1
  1. 1.Department of Gynecology and ObstetricsCantonal Hospital FrauenfeldFrauenfeldSwitzerland
  2. 2.Institute of Pathology, Medical University GrazGrazAustria

Personalised recommendations